Amgen Inc. Available-for-sale Securities, Gross Realized Losses
Amgen Inc. (AMGN) reported Available-for-sale Securities, Gross Realized Losses of $151.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-25.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses · last filed 2018-04-25
- Amgen Inc. available-for-sale securities, gross realized losses for the quarter ending 2018-03-31 was $151.00M, a 79.76% increase year-over-year.
- Amgen Inc. available-for-sale securities, gross realized losses for the quarter ending 2017-12-31 was $30.00M, a 44.44% decline year-over-year.
- Amgen Inc. available-for-sale securities, gross realized losses for the quarter ending 2017-09-30 was $12.00M, a 93.75% decline year-over-year.
- Amgen Inc. available-for-sale securities, gross realized losses for the quarter ending 2017-06-30 was $87.00M, a 61.11% increase year-over-year.
- Amgen Inc. available-for-sale securities, gross realized losses for fiscal 2017 was $213.00M, a 41.96% decline from fiscal 2016.
- Amgen Inc. available-for-sale securities, gross realized losses for fiscal 2016 was $367.00M, a 76.44% increase from fiscal 2015.
- Amgen Inc. available-for-sale securities, gross realized losses for fiscal 2015 was $208.00M, a 38.67% increase from fiscal 2014.
- Amgen Inc. available-for-sale securities, gross realized losses for fiscal 2014 was $150.00M.
| Period end | Available-for-sale Securities, Gross Realized Losses 3 month | Available-for-sale Securities, Gross Realized Losses 6 month | Available-for-sale Securities, Gross Realized Losses 9 month | Available-for-sale Securities, Gross Realized Losses 12 month |
|---|---|---|---|---|
| 2018-03-31 | $151.00M 10-Q · filed 2018-04-25 | $181.00M derived: sum of 2 quarters · filed 2018-04-25 | $193.00M derived: sum of 3 quarters · filed 2018-04-25 | $280.00M derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $42.00M derived: sum of 2 quarters · filed 2018-02-13 | $129.00M derived: sum of 3 quarters · filed 2018-02-13 | $213.00M 10-K · filed 2018-02-13 |
| 2017-09-30 | $12.00M 10-Q · filed 2017-10-26 | $99.00M derived: sum of 2 quarters · filed 2017-10-26 | $183.00M 10-Q · filed 2017-10-26 | $237.00M derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-06-30 | $87.00M 10-Q · filed 2017-07-26 | $171.00M 10-Q · filed 2017-07-26 | $225.00M derived: sum of 3 quarters · filed 2018-04-25 | $417.00M derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-03-31 | $84.00M 10-Q · filed 2018-04-25 | $138.00M derived: sum of 2 quarters · filed 2018-04-25 | $330.00M derived: sum of 3 quarters · filed 2018-04-25 | $384.00M derived: sum of 4 quarters · filed 2018-04-25 |
| 2016-12-31 | $54.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $246.00M derived: sum of 2 quarters · filed 2018-02-13 | $300.00M derived: sum of 3 quarters · filed 2018-02-13 | $367.00M 10-K · filed 2018-02-13 |
| 2016-09-30 | $192.00M 10-Q · filed 2017-10-26 | $246.00M derived: sum of 2 quarters · filed 2017-10-26 | $313.00M 10-Q · filed 2017-10-26 | $365.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $54.00M 10-Q · filed 2017-07-26 | $121.00M 10-Q · filed 2017-07-26 | $173.00M derived: sum of 3 quarters · filed 2018-02-13 | $231.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $67.00M 10-Q · filed 2017-04-27 | $119.00M derived: sum of 2 quarters · filed 2018-02-13 | $177.00M derived: sum of 3 quarters · filed 2018-02-13 | $204.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $52.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $110.00M derived: sum of 2 quarters · filed 2018-02-13 | $137.00M derived: sum of 3 quarters · filed 2018-02-13 | $208.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | $58.00M 10-Q · filed 2016-10-28 | $85.00M derived: sum of 2 quarters · filed 2016-10-28 | $156.00M 10-Q · filed 2016-10-28 | $235.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $27.00M 10-Q · filed 2016-07-29 | $98.00M 10-Q · filed 2016-07-29 | $177.00M derived: sum of 3 quarters · filed 2017-02-14 | $205.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $71.00M 10-Q · filed 2016-05-02 | $150.00M derived: sum of 2 quarters · filed 2017-02-14 | $178.00M derived: sum of 3 quarters · filed 2017-02-14 | $195.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $79.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $107.00M derived: sum of 2 quarters · filed 2017-02-14 | $124.00M derived: sum of 3 quarters · filed 2017-02-14 | $150.00M 10-K · filed 2017-02-14 |
| 2014-09-30 | $28.00M 10-Q · filed 2015-11-02 | $45.00M derived: sum of 2 quarters · filed 2015-11-02 | $71.00M 10-Q · filed 2015-11-02 | $84.00M derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-06-30 | $17.00M 10-Q · filed 2015-08-05 | $43.00M 10-Q · filed 2015-08-05 | $56.00M derived: sum of 3 quarters · filed 2016-10-31 | $82.00M derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-03-31 | $26.00M 10-Q · filed 2015-04-27 | $39.00M derived: sum of 2 quarters · filed 2016-10-31 | $65.00M derived: sum of 3 quarters · filed 2016-10-31 | $91.00M derived: sum of 4 quarters · filed 2016-10-31 |
| 2013-12-31 | $13.00M derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | $39.00M derived: sum of 2 quarters · filed 2016-10-31 | $65.00M derived: sum of 3 quarters · filed 2016-10-31 | $83.00M 8-K · filed 2016-10-31 |
| 2013-09-30 | $26.00M 10-Q · filed 2014-10-29 | $52.00M derived: sum of 2 quarters · filed 2014-10-29 | $70.00M 10-Q · filed 2014-10-29 | $83.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $26.00M 10-Q · filed 2014-08-05 | $44.00M 10-Q · filed 2014-08-05 | $57.00M derived: sum of 3 quarters · filed 2015-02-19 | $68.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $18.00M 10-Q · filed 2014-04-30 | $31.00M derived: sum of 2 quarters · filed 2015-02-19 | $42.00M derived: sum of 3 quarters · filed 2015-02-19 | $53.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $24.00M derived: sum of 2 quarters · filed 2015-02-19 | $35.00M derived: sum of 3 quarters · filed 2015-02-19 | $54.00M 10-K · filed 2015-02-19 |
| 2012-09-30 | $11.00M 10-Q · filed 2013-10-29 | $22.00M derived: sum of 2 quarters · filed 2013-10-29 | $41.00M 10-Q · filed 2013-10-29 | $53.00M derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-06-30 | $11.00M 10-Q · filed 2013-08-06 | $30.00M 10-Q · filed 2013-08-06 | $42.00M derived: sum of 3 quarters · filed 2014-02-24 | $54.00M derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-03-31 | $19.00M 10-Q · filed 2013-05-03 | $31.00M derived: sum of 2 quarters · filed 2014-02-24 | $43.00M derived: sum of 3 quarters · filed 2014-02-24 | $48.00M derived: sum of 4 quarters · filed 2014-02-24 |
| 2011-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $24.00M derived: sum of 2 quarters · filed 2014-02-24 | $29.00M derived: sum of 3 quarters · filed 2014-02-24 | $37.00M 10-K · filed 2014-02-24 |
| 2011-09-30 | $12.00M 10-Q · filed 2012-11-06 | $17.00M derived: sum of 2 quarters · filed 2012-11-06 | $25.00M 10-Q · filed 2012-11-06 | $36.00M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $5.00M 10-Q · filed 2012-08-08 | $13.00M 10-Q · filed 2012-08-08 | $24.00M derived: sum of 3 quarters · filed 2013-02-27 | $35.00M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $8.00M 10-Q · filed 2012-05-08 | $19.00M derived: sum of 2 quarters · filed 2013-02-27 | $30.00M derived: sum of 3 quarters · filed 2013-02-27 | $32.00M derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $22.00M derived: sum of 2 quarters · filed 2013-02-27 | $24.00M derived: sum of 3 quarters · filed 2013-02-27 | $25.00M 10-K · filed 2013-02-27 |
| 2010-09-30 | $11.00M 10-Q · filed 2011-11-04 | $13.00M derived: sum of 2 quarters · filed 2011-11-04 | $14.00M 10-Q · filed 2011-11-04 | $21.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $2.00M 10-Q · filed 2011-08-08 | $3.00M 10-Q · filed 2011-08-08 | $10.00M derived: sum of 3 quarters · filed 2012-02-29 | $18.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $2.00M 10-Q · filed 2011-05-10 | $8.00M derived: sum of 2 quarters · filed 2012-02-29 | $16.00M derived: sum of 3 quarters · filed 2012-02-29 | $31.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $14.00M derived: sum of 2 quarters · filed 2012-02-29 | $29.00M derived: sum of 3 quarters · filed 2012-02-29 | $62.00M 10-K · filed 2012-02-29 |
| 2009-09-30 | $8.00M 10-Q · filed 2010-11-08 | $23.00M derived: sum of 2 quarters · filed 2010-11-08 | $56.00M 10-Q · filed 2010-11-08 | |
| 2009-06-30 | $15.00M 10-Q · filed 2010-08-09 | $48.00M 10-Q · filed 2010-08-09 | ||
| 2008-12-31 | $49.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |